---
title: Training With Mobile Application in Breast Cancer
nct_id: NCT04315012
overall_status: COMPLETED
phase: NA
sponsor: Izmir Bakircay University
study_type: INTERVENTIONAL
primary_condition: Breast Cancer
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04315012.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04315012"
ct_last_update_post_date: 2020-04-01
last_seen_at: "2026-05-12T07:16:14.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Training With Mobile Application in Breast Cancer

**Official Title:** The Effect of E-mobile Education on The Quality of Life in Breast Cancer Women

**NCT ID:** [NCT04315012](https://clinicaltrials.gov/study/NCT04315012)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 64
- **Lead Sponsor:** Izmir Bakircay University
- **Collaborators:** Ege University
- **Conditions:** Breast Cancer
- **Start Date:** 2018-01-10
- **Completion Date:** 2018-04-17
- **CT.gov Last Update:** 2020-04-01

## Brief Summary

Endocrine hormonal therapy (EHT) applied to avoid recurrence and metastasis of the breast cancer has also side effects which do not threaten life; however, it does negatively effects quality of life. The objective of this study was to determine the effects on quality of life of a mobile app-based (e-mobile) education for supportive care of patients with breast cancer receiving adjuvant endocrine hormonal therapy. The data were collected to with face to face and/or telephone interviews at 2 time points: prior to the initiation (T0) and after the completion (T1) of mobile app-based education. Patients were received education via mobile app for 12 weeks during which they were contacted in every 15 days; a mobile app-based (e-mobile) education was provided, including information about breast cancer definition, treatment process, symptoms management, adequate nutrition, regular physical activity and coping with stress. In this process, the control group patients were provided with standard care.

## Detailed Description

Mobile devices have an increasing role for the patient care and its use in the field of oncology creates promising opportunities for supportive cancer care and patient education. Mobile applications were established for the supportive cancer care but their area of use is limited. Although there are many field specific medical mobile applications, there are few training programs for the benefit of patients. However, these are innovative tools and provide accessibility, individual training and consultancy in order for the patients to be able to cope with side effects of the treatment; thus, improving their quality of life, symptom management and distress.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosed with primary breast cancer,
* Non-metastatic,
* Hormone receptor positive (ER positive and/or PR positive)
* For whom adjuvant EHT was implemented at least for three months

Exclusion Criteria:

* Diagnosed with secondary breast cancer,
* Metastatic,
* Hormone receptor negative (ER negative and/or PR negative)
```

## Arms

- **Receiving mobile app-based education** (EXPERIMENTAL) — to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.
- **Standart** (NO_INTERVENTION) — not to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.

## Interventions

- **receive mobile app-based education** (OTHER) — to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.

## Primary Outcomes

- **Functional Assessment for the Cancer Treatment - Endocrine Symptoms Quality of Life Scale (FACT-ES QLS)** _(time frame: Change from Baseline Quality of Life at 12 weeks)_ — The scale includes five sub dimensions and total of 46 items measuring the well-being of patients within the course of the last 7 days. There are sub dimensions for each of the following: physical well-being (7 items, 0-28 points), social/family well-being (7 items, 0-28 points), emotional well-being (6 items, 0-24 points), functional well-being (7 items, 0-28 points) and endocrine symptoms (19 items, 0-76 points). Endocrine symptoms' subdimension contains symptoms related to the side effects of EHT. The range of total points of the scale is 0-184. It shows that quality of life increases as total points of the scale increase. It shows that quality of life decreases as total points of the scale decrease.
- **National Comprehensive Cancer Network (NCCN) Distress Thermometer** _(time frame: Change from Baseline Distress at 12 weeks)_ — Patients may specify the severity of the distress level they experienced related to their problems, with these numbers, within the course of last 7 days. No distress is specified with "0" point, a severe amount of distress is specified with "10" points.

## Locations (1)

- İzmir Bakırçay University, Izmir, Turkey (Türkiye)

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.i̇zmir bakırçay university|izmir||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04315012.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04315012*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*